Entos, Inc., a San Diego, CA-based creator of a platform combining AI-driven technology and automated synthetic development to design small-molecule therapeutics, closed a $53m Series A financing. The round was led by Coatue and Catalio Capital Management, with participation from OrbiMed and Sequoia Capital as well as existing investors Nexus Ventures and Freeflow. As part of the funding, Aaron Weiner, Managing Director and Head of Healthcare at Coatue, and R. Jacob Vogelstein, Ph.D., Co-Founder and Managing Partner of Catalio, joined Entos’ Board of Directors that includes Tom Miller, Co-...